Addex mglu2pam demonstrates potential in substance use disorder

Data published in neuropharmacology shows mglu2 pam s attenuate oxycodone use and potential as a novel treatment f or opioid use disorder ad hoc announcement pursuant to art. 53 lr geneva, switzerland, july 2 4 , 202 3 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced data showing that administration of a metabotropic glutamate 2 (mglu2) positive allosteric modulator significantly reduces oxycodone self-administration in preclinical models, supporting a potential role in opioid use disorder.
ADXN Ratings Summary
ADXN Quant Ranking